Therapy with wortmannin or LY294002 increased I B phosphorylation leading to a decline in the appearance of I T. Densitometric analysis showed a reduction in I W appearance after wortmannin or LY294002 therapy 20% JZL184 clinical trial and 23% in LBR, 23% and twenty four hours in LBR D160; 29-30 and 3500-4000 in LBR V160, respectively. We next examined the game of this transcription factor by EMSA assay, because increased p I B seems to cause activation of NF W. We discovered that wortmannin enhanced NF B activity in a dose-dependent manner Fig. 7B. These data demonstrate that inhibition of PI3K/Akt pathway stimulates NF B pathway. In this study we evaluated the correlation of the PI3K/Akt signaling pathway with multidrug resistance and the NF W survival pathway. We confirmed the resistant cell lines, LBR D160 and LBR V160, offered higher PI3K/Akt activity compared to the one, which will be prior to the MDR phenotype. The production of PIP3 and Endosymbiotic theory the expression of p Akt, which reveal PI3K activity, were enhanced in the resistant cell lines, but the expression of PI3K p85 was reduced in LBR D160 when put next with the other cell lines. Because in these cell lines other isoforms distinctive from the regulatory subunit p85 could lead to PI3K activity these discrepancies could be. In fact, mutants of the regulatory subunit of PI3K p65 PI3K in a thymic lymphoma cell line and p76 in a human lymphoma cell line have already been described. Both proteins subscribe to cellular transformation and induce the kinase activity of PI3K. We also confirmed that the expression of p Akt and survivinwas decreased afterwortmannin orLY294002 treatment in the three cell lines without adjusting Akt expression. Our results are in line with previous reports suggesting that survivin is under control. Subsequently, inhibition of the PI3K/Akt pathway with wortmannin or LY294002 caused larger apoptosis levels in LBR V160 and LBR D160 than in LBR, ergo suggesting that this pathway might be essential for the survival of MDR lymphoma cell lines. The chemotherapeutic agent vincristine however not doxorubicin could increase the PI3K/Akt natural product library process in-the three cell lines as shown by improved PIP3 production and p Akt appearance. Likely, PI3K/Akt inhibition sensitized the cell lines to VCR but not to DOX induced apoptosis. However some authors have noted that inhibition of PI3K chemosensitize cancer cells to DOX, others have shown that LY294002 synergistically raise the cytotoxicity caused by providers like vincristine or paclitaxel. Our results show that in these lymphoma cell lines VCR and DOX have different effects on the PI3K/Akt pathway and that inhibition of this signaling cascade chemosensitizes cancer cells only to the antimicrotubule agent.